U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049107) titled 'Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects' on June 24.
Brief Summary: This study is a single-center, open-label, sequential drug interaction study
The primary objectives are:
To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Health Volunteer
Intervention:
DRUG: HRS-8427
HRS-8427
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Published by HT Digital Content Services ...